Pirfenidone for primary Sjögren's syndrome-related fibrotic interstitial pneumonia

Yasunori Enomoto, Yutaro Nakamura, Thomas V. Colby, Naoki Inui, Takafumi Suda

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Primary Sjögren's syndrome-related interstitial pneumonia (pSS-IP) is occasionally progressive even with immunosuppressive therapy and new treatment options are warranted. A 42-year-old woman was diagnosed with pSS-IP with pathological usual interstitial pneumonia pattern. Although her forced vital capacity (FVC) had temporarily improved after prednisolone therapy, it deteriorated during the prednisolone tapering off period. Therefore, pirfenidone was added in conjunction with prednisolone. During the 12-month treatment period, her FVC was almost stable. A 62-year-old man, a current heavy smoker, was diagnosed with pSS-IP. Chest computed tomography showed bilateral honeycombing with ground-glass attenuation on a background of emphysema. He gradually developed dyspnea on exertion and his FVC deteriorated. Hence, pirfenidone was administered as a monotherapy. Six months later, his FVC and exercise tolerance had significantly improved. Pirfenidone might have a role for the treatment of pSS-IP. (Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 91-96).

Original languageEnglish (US)
Pages (from-to)91-96
Number of pages6
JournalSarcoidosis Vasculitis and Diffuse Lung Diseases
Issue number1
StatePublished - 2017


  • Interstitial pneumonia
  • Pirfenidone
  • Sjogren's syndrome

ASJC Scopus subject areas

  • Internal Medicine
  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Pirfenidone for primary Sjögren's syndrome-related fibrotic interstitial pneumonia'. Together they form a unique fingerprint.

Cite this